Indeed, a recent large phase II trial in breast cancer is already using CTC DNA analysis to match key driver mutations in CTCs, including PTEN inactivating mutations, to select personalized therapies for patients, such as AKT-targeted therapy for PTEN-deficient patients [80]. The gene discussed is AKT1; the disease is breast carcinoma.